Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jan 02, 2022 | Director, Chief Operating Officer | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Form 4 | 27,946 | $11.55 | 411,725 | |
| Sep 29, 2014 | VP, Legal & IP | Open market or private purchase of non-derivative or derivative security | Form 4 | 28,208 | $6.09 | 78,208 | |
| Sep 29, 2014 | VP, Legal & IP | Open market or private sale of non-derivative or derivative security | Form 4 | 28,208 | $6.09 | 50,000 | |
| Feb 20, 2008 | Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 28,481 | $9.62 | 687,864 | |
| Feb 20, 2008 | Director, Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 28,481 | $9.62 | 687,864 | |
| May 25, 2021 | Director | Open market or private purchase of non-derivative or derivative security | Form 4 | 28,605 | $8.74 | 50,310 | |
| Aug 31, 2020 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 28,750 | $6.10 | 191,954 | |
| Aug 31, 2020 | Chief Medical Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 28,750 | $14.74 | 163,204 | |
| Aug 31, 2020 | Chief Medical Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 28,750 | -- | 1,250 | |
| Jan 09, 2024 | Director, President and CEO | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4/A | 28,810 | -- | 927,773 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.